ArticleEXCLI journal2020
Unrevealing sequence and structural features of novel coronavirus using
Article in EXCLI journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 108 citations in OpenAlex.
- Design and synthesis of novel sulfa-azo dyes: a sustainable approach to textile dyeing combined with microwave energy.RSC advances · 2026Article
- Pathogenesis of COVID19 and the applications of US FDA-approved repurposed antiviral drugs to combat SARS-CoV-2 in Saudi Arabia: A recent update by review of literature.Saudi journal of biological sciences · 2024Review
- Application of artificial intelligence (AI) to control COVID-19 pandemic: Current status and future prospects.Heliyon · 2024Review
- Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.Antiviral research · 2023Article
- A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J · 2022Review
- Novel indolo [3,2-c]isoquinoline-5-one-6-yl [1,2,4]triazolo [3,4-b] [1,3,4]thiadiazole analogues: Design, synthesis, anticancer activity, docking with SARS-CoV-2 Omicron protease and MESP/TD-DFT approaches.Journal of molecular structure · 2022Article
- Coronavirus enzyme inhibitors-experimentally proven natural compounds from plants.Journal of microbiology (Seoul, Korea) · 2022Review
- Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors.ACS medicinal chemistry letters · 2022Article
- Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease.Journal of biomolecular structure & dynamics · 2022Article
- Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis.Pathogens (Basel, Switzerland) · 2021Article
- Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.European journal of medicinal chemistry reports · 2021Review
- The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.Topics in current chemistry (Cham) · 2021Review
- Article
- Comparative protein structure network analysis on 3CLProteins · 2021Article
- Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CLJournal of biomolecular structure & dynamics · 2021Article
- Repurposing cefuroxime for treatment of COVID-19: a scoping review ofJournal of biomolecular structure & dynamics · 2021Article
- A novel nano therapeutic using convalescent plasma derived exosomal (CPChemico-biological interactions · 2021Article
- Targeting SARS-CoV-2 nonstructural protein 15 endoribonuclease: anFuture virology · 2021Article
- New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Computational search for drug repurposing to identify potential inhibitors against SARS-COV-2 using Molecular Docking, QTAIM and IQA methods in viral Spike protein - Human ACE2 interface.Journal of molecular structure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct-acting antivirals are effective tools to control viral infections. SARS-CoV-2 is a coronavirus associated with the epidemiological outbreak in late 2019. Previous reports showed that HIV-1 protease inhibitors could block SARS-CoV main protease. Based on that and using an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.